ArticleBMC health services research2022

Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study.

Carlos Escobar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.